lower schreef op 21 februari 2018 10:06:
[...]
Precies even de trials tegen elkaar aan houden.
www.biocryst.com/application/files/17...clinicaltrials.gov/ct2/show/NCT02870972Waarschijnlijk altijd Ruconest meeleveren voor de breakthrough attacks.
Dat maakt de medicatie zou verschikkelijk duur dat hele breakthrough verhaal van de concurrenten van Pharming.
www.ruconest.com/RUCONEST is a C1 esterase inhibitor, or C1-INH, indicated for the treatment of acute attacks in adult and adolescent patients with HAE.
A PLASMA-FREE C1-INH, which has no risk of passing on human viruses
Rapid onset of relief, with a median
time of 75 to 90 minutes
Approximately 9 of 10 people needed
JUST ONE DOSE
Symptom relief lasted for at least
3 days in 93% of attacksThere is a RELIABLE SUPPLY of RUCONEST